A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Apr 2018
At a glance
- Drugs ASN 003 (Primary)
- Indications Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Asana BioSciences
- 10 Apr 2018 According to an Asana BioSciences media release, the data will be presented at the American Association for Cancer Research (AACR) Annual Meeting.
- 06 Apr 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 06 Apr 2018 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History